company background image
ICAD

iCAD NasdaqCM:ICAD Stock Report

Last Price

US$3.59

Market Cap

US$90.4m

7D

-3.0%

1Y

-76.6%

Updated

15 May, 2022

Data

Company Financials +
ICAD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ICAD Stock Overview

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States.

iCAD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iCAD
Historical stock prices
Current Share PriceUS$3.59
52 Week HighUS$19.00
52 Week LowUS$2.91
Beta1.28
1 Month Change-0.28%
3 Month Change-31.36%
1 Year Change-76.60%
3 Year Change-36.23%
5 Year Change-21.44%
Change since IPO-92.91%

Recent News & Updates

Shareholder Returns

ICADUS Healthcare ServicesUS Market
7D-3.0%-2.9%-2.5%
1Y-76.6%-35.3%-10.4%

Return vs Industry: ICAD underperformed the US Healthcare Services industry which returned -35.3% over the past year.

Return vs Market: ICAD underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is ICAD's price volatile compared to industry and market?
ICAD volatility
ICAD Average Weekly Movement10.1%
Healthcare Services Industry Average Movement12.0%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: ICAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ICAD's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984137Stacey Stevenshttps://www.icadmed.com

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.

iCAD Fundamentals Summary

How do iCAD's earnings and revenue compare to its market cap?
ICAD fundamental statistics
Market CapUS$90.40m
Earnings (TTM)-US$13.15m
Revenue (TTM)US$32.52m

2.8x

P/S Ratio

-6.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICAD income statement (TTM)
RevenueUS$32.52m
Cost of RevenueUS$8.94m
Gross ProfitUS$23.58m
Other ExpensesUS$36.73m
Earnings-US$13.15m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin72.51%
Net Profit Margin-40.43%
Debt/Equity Ratio0%

How did ICAD perform over the long term?

See historical performance and comparison

Valuation

Is iCAD undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.07x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ICAD is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: ICAD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICAD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ICAD's PB Ratio (2.1x) is in line with the US Healthcare Services industry average.


Future Growth

How is iCAD forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


86.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ICAD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ICAD's is expected to become profitable in the next 3 years.

Revenue vs Market: ICAD's revenue (27.5% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: ICAD's revenue (27.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ICAD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has iCAD performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-1.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ICAD is currently unprofitable.

Growing Profit Margin: ICAD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICAD is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare ICAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICAD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (6.6%).


Return on Equity

High ROE: ICAD has a negative Return on Equity (-30.05%), as it is currently unprofitable.


Financial Health

How is iCAD's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ICAD's short term assets ($47.9M) exceed its short term liabilities ($14.5M).

Long Term Liabilities: ICAD's short term assets ($47.9M) exceed its long term liabilities ($631.0K).


Debt to Equity History and Analysis

Debt Level: ICAD is debt free.

Reducing Debt: ICAD currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICAD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ICAD has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 11.5% each year.


Dividend

What is iCAD current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICAD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ICAD has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Stacey Stevens (53 yo)

3.17yrs

Tenure

US$773,406

Compensation

Ms. Stacey M. Stevens is Chief Executive Officer and Director at iCAD, Inc. since March 1, 2022. She has been President of iCAD, Inc. since March 28, 2019. Ms. Stevens served as Executive Vice President an...


CEO Compensation Analysis

Compensation vs Market: Stacey's total compensation ($USD773.41K) is about average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Stacey's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ICAD's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: ICAD's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ICAD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

iCAD, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: iCAD, Inc.
  • Ticker: ICAD
  • Exchange: NasdaqCM
  • Founded: 1984
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: US$90.403m
  • Shares outstanding: 25.18m
  • Website: https://www.icadmed.com

Number of Employees


Location

  • iCAD, Inc.
  • 98 Spit Brook Road
  • Suite 100
  • Nashua
  • New Hampshire
  • 3062
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.